The NF1 gene revisited -from bench to bedside

Oncotarget

Volumn 5, Issue 15, 2014, Pages 5873-5892

  Yap, Yoon Sim ^a,b   McPherson, John R ^c   Ong, Choon Kiat ^a,c   Rozen, Steven G ^c   Teh, Bin Tean ^a,c,d   Lee, Ann S G ^a,c,e   Callen, David F ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cancer; Neurofibromatosis type 1; Neurofibromin; NF1

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ALISERTIB; ALPHA2A INTERFERON; ERLOTINIB; EVEROLIMUS; IMATINIB; ISOTRETINOIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NEUROFIBROMIN; PIRFENIDONE; PLACEBO; RAPAMYCIN; RETASPIMYCIN; SELUMETINIB; SORAFENIB; THALIDOMIDE; TIPIFARNIB;

ARTICLE; BRAIN TUMOR; BREAST TUMOR; CANCER INHIBITION; COLORECTAL CARCINOMA; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; EPIGENETICS; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC PROCEDURES; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MELANOMA; MOLECULAR DIAGNOSIS; NEUROFIBROMA; NEUROFIBROMATOSIS; NEXT GENERATION SEQUENCING; NF1 GENE; NONHUMAN; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; NEOPLASM;

ANIMALS; GENES, NEUROFIBROMATOSIS 1; HUMANS; NEOPLASMS; NEUROFIBROMIN 1;

EID: 84906226934     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2194     Document Type: Article

References (186)

1. Brosius S. A history of von Recklinghausen's NF1. J Hist Neurosci. 2010; 19(4):333-348.
2. Rasmussen SA and Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000; 151(1):33-40.
3. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R and White R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990; 62(3):599-608.
4. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R and O'Connell P. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990; 62(1):193-201.
5. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P and Cawthon RM. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990; 63(4):843-849.
6. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M and Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990; 63(4):851-859.
7. Bollag G and McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature. 1991; 351(6327):576-579.
8. Sorensen SA, Mulvihill JJ and Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986; 314(16):1010-1015.
9. Brems H, Beert E, de Ravel T and Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. The Lancet Oncology. 2009; 10(5):508-515.
10. Schroeder RD, Angelo LS and Kurzrock R. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget. 2014; 5(1):67-77.
11. Griffiths S, Thompson P, Frayling I and Upadhyaya M. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer. 2007; 6(1):21-34.
12. Easton DF, Ponder MA, Huson SM and Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993; 53(2):305-313.
13. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988; 45(5):575-578.
14. Larizza L, Gervasini C, Natacci F and Riva P. Developmental abnormalities and cancer predisposition in neurofibromatosis type 1. Curr Mol Med. 2009; 9(5):634-653.
15. Upadhyaya M, Ruggieri M, Maynard J, Osborn M, Hartog C, Mudd S, Penttinen M, Cordeiro I, Ponder M, Ponder BA, Krawczak M and Cooper DN. Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet. 1998; 102(5):591-597.
16. Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Barnicoat A, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007; 80(1):140-151.
17. Grisart B, Rack K, Vidrequin S, Hilbert P, Deltenre P, Verellen-Dumoulin C and Destrée A. NF1 microduplication first clinical report: association with mild mental retardation, early onset of baldness and dental enamel hypoplasia? Eur J Hum Genet. 2008; 16(3):305-311.
18. Moles KJ, Gowans GC, Gedela S, Beversdorf D, Yu A, Seaver LH, Schultz RA, Rosenfeld JA, Torchia BS and Shaffer LG. NF1 microduplications: identification of seven nonrelated individuals provides further characterization of the phenotype. Genet Med. 2012; 14(5):508-514.
19. Pasmant E, Vidaud M, Vidaud D and Wolkenstein P. Neurofibromatosis type 1: from genotype to phenotype. J Med Genet. 2012; 49(8):483-489.
20. Roth TM, Petty EM and Barald KF. The role of steroid hormones in the NF1 phenotype: focus on pregnancy. Am J Med Genet A. 2008; 146A(12):1624-1633.
21. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J and Mitchell AL. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990; 249(4965):181-186.
22. Li Y, O'Connell P, Breidenbach HH, Cawthon R, Stevens J, Xu G, Neil S, Robertson M, White R and Viskochil D. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics. 1995; 25(1):9-18.
23. Viskochil D, Cawthon R, O'Connell P, Xu GF, Stevens J, Culver M, Carey J and White R. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol. 1991; 11(2):906-912.
24. Cawthon RM, Andersen LB, Buchberg AM, Xu GF, O'Connell P, Viskochil D, Weiss RB, Wallace MR, Marchuk DA and Culver M. cDNA sequence and genomic structure of EV12B, a gene lying within an intron of the neurofibromatosis type 1 gene. Genomics. 1991; 9(3):446-460.
25. Nordlund M, Gu X, Shipley MT and Ratner N. Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons. J Neurosci. 1993; 13(4):1588-1600.
26. Suzuki H, Takahashi K, Kubota Y and Shibahara S. Molecular cloning of a cDNA coding for neurofibromatosis type 1 protein isoform lacking the domain related to ras GTPase-activating protein. Biochem Biophys Res Commun. 1992; 187(2):984-990.
27. Andersen LB, Ballester R, Marchuk DA, Chang E, Gutmann DH, Saulino AM, Camonis J, Wigler M and Collins FS. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol. 1993; 13(1):487-495.
28. Cacev T, Radosevic S, Spaventi R, Pavelic K and Kapitanovic S. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut. 2005; 54(8):1129-1135.
29. Iyengar TD, Ng S, Lau CC, Welch WR, Bell DA, Berkowitz RS and Mok SC. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogene. 1999; 18(1):257-262.
30. Marrero D, Peralta R, Valdivia A, De la Mora A, Romero P, Parra M, Mendoza N, Mendoza M, Rodriguez D, Camacho E, Duarte A, Castelazo G, Vanegas E, Garcia I, Vargas C, Arenas D, et al. The neurofibromin 1 type I isoform predominance characterises female population affected by sporadic breast cancer: preliminary data. J Clin Pathol. 2012; 65(5):419-423.
31. Uchida T, Matozaki T, Suzuki T, Matsuda K, Wada K, Nakano O, Konda Y, Nishisaki H, Nagao M and Sakamoto C. Expression of two types of neurofibromatosis type 1 gene transcripts in gastric cancers and comparison of GAP activities. Biochem Biophys Res Commun. 1992; 187(1):332-339.
32. Gutmann DH, Geist RT, Rose K and Wright DE. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues. Dev Dyn. 1995; 202(3):302-311.
33. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF and Copeland NG. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994; 8(9):1019-1029.
34. Danglot G, Régnier V, Fauvet D, Vassal G, Kujas M and Bernheim A. Neurofibromatosis 1 (NF1) mRNAs expressed in the central nervous system are differentially spliced in the 5' part of the gene. Hum Mol Genet. 1995; 4(5):915-920.
35. Gutmann DH, Zhang Y and Hirbe A. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Ann Neurol. 1999; 46(5):777-782.
36. Kaufmann D, Müller R, Kenner O, Leistner W, Hein C, Vogel W and Bartelt B. The N-terminal splice product NF1-10a-2 of the NF1 gene codes for a transmembrane segment. Biochem Biophys Res Commun. 2002; 294(2):496-503.
37. Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, Moose R, Virdi G, Roux K, Bauer M, Rojiani AM, Maria BL, Muir D and Wallace MR. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer. 2000; 28(4):425-431.
38. John AM, Ruggieri M, Ferner R and Upadhyaya M. A search for evidence of somatic mutations in the NF1 gene. J Med Genet. 2000; 37(1):44-49.
39. Eisenbarth I, Beyer K, Krone W and Assum G. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am J Hum Genet. 2000; 66(2):393-401.
40. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA and Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. The Lancet Oncology. 2009; 10(3):267-277.
41. Gutmann DH and Giovannini M. Mouse Models of Neurofibromatosis 1 and 2. Neoplasia. 2002; 4(4):279-290.
42. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A and Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994; 7(3):353-361.
43. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT and Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999; 286(5447):2172-2176.
44. Johannessen CM, Reczek EE, James MF, Brems H, Legius E and Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA. 2005; 102(24):8573-8578.
45. Mangoura D, Sun Y, Li C, Singh D, Gutmann DH, Flores A, Ahmed M and Vallianatos G. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene. 2006; 25(5):735-745.
46. Xu H and Gutmann DH. Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain research. 1997; 759(1):149-152.
47. Boyanapalli M, Lahoud OB, Messiaen L, Kim B, Anderle de Sylor MS, Duckett SJ, Somara S and Mikol DD. Neurofibromin binds to caveolin-1 and regulates ras, FAK, and Akt. Biochem Biophys Res Commun. 2006; 340(4):1200-1208.
48. Mattocks C, Baralle D, Tarpey P, ffrench-Constant C, Bobrow M and Whittaker J. Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain. J Med Genet. 2004; 41(4).
49. Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kücükceylan N, Abdel-Nour M, Gewies A, Peters H, Kaufmann D, Buske A, Tinschert S and Nürnberg P. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet. 2000; 66(3):790-818.
50. Tong J, Hannan F, Zhu Y, Bernards A and Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci. 2002; 5(2):95-96.
51. Dasgupta B, Dugan LL and Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci. 2003; 23(26):8949-8954.
52. Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman DM and Gutmann DH. Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem. 1999; 274(36):25842-25848.
53. Brown JA, Gianino SM and Gutmann DH. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci. 2010; 30(16):5579-5589.
54. Shapira S, Barkan B, Friedman E, Fridman E, Kloog Y and Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Rasindependent pathways. Cell Death Differ. 2007; 14(5):895-906.
55. Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, Hara T, Ichikawa Y, Matsumoto K, Fujii K and Saya H. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J Biol Chem. 2005; 280(47):39524-39533.
56. Hsueh YP, Roberts AM, Volta M, Sheng M and Roberts RG. Bipartite interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans. J Neurosci. 2001; 21(11):3764-3770.
57. Kweh F, Zheng M, Kurenova E, Wallace M, Golubovskaya V and Cance WG. Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase. Mol Carcinog. 2009; 48(11):1005-1017.
58. Arima Y, Hayashi H, Kamata K, Goto TM, Sasaki M, Kuramochi A and Saya H. Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1. Exp Dermatol. 2010; 19(8):e136-141.
59. Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, Bronson RT, Whitesell L and Lindquist S. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest. 2012; 122(10):3742-3754.
60. Zöller ME, Rembeck B, Odén A, Samuelsson M and Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997; 79(11):2125-2131.
61. Patil S and Chamberlain RS. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist. 2012; 17(1):101-116.
62. Laycock-van Spyk S, Thomas N, Cooper DN and Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics. 2011; 5(6):623-690.
63. Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E and Evans DGR. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet. 2007; 44(8):481-484.
64. Wang X, Levin AM, Smolinski SE, Vigneau FD, Levin NK and Tainsky MA. Breast cancer and other neoplasms in women with neurofibromatosis type 1: A retrospective review of cases in the Detroit metropolitan area. American Journal of Medical Genetics Part A. 2012; 158A(12):3061-3064.
65. Teh BT, Birrell G, Farrell A, Leonard JH, Walters MK, Palmer JM, Ramsay JR, Schlect DJ, Furnival C, Lavin MF, Bennett I and Hayward NK. Breast cancer in six women with neurofibromatosis type 1. Breast. 1997; 6(3):155-160.
66. Yap YS, Wong J, Chan M, Yong WS, Ong KW, Ngeow J, Tan B, Madhukumar P, Tan MH, Ang P, Teh BT, Tan PH, Lee A. Clinical and Pathological Characteristics of Breast Cancer in Women with Neurofibromatosis Type 1. Cancer Research. 2012; 72(24S;1024): P3-08-09.
67. Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME and Evans DGR. Second Primary Tumors in Neurofibromatosis 1 Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy. JCO. 2006; 24(16):2570-2575.
68. Choi G, Huang B, Pinarbasi E, Braunstein SE, Horvai AE, Kogan S, Bhatia S, Faddegon B and Nakamura JL. Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. Cancer Res. 2012; 72(24):6425-6434.
69. Chao RC, Pyzel U, Fridlyand J, Kuo Y-M, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG and Shannon KM. Therapyinduced malignant neoplasms in Nf1 mutant mice. Cancer Cell. 2005; 8(4):337-348.
70. Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO and Shannon K. Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res. 2011; 71(1):106-115.
71. Pemov A, Park C, Reilly KM and Stewart DR. Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency. BMC Genomics. 2010; 11.
72. Halazonetis TD, Gorgoulis VG and Bartek J. An oncogeneinduced DNA damage model for cancer development. Science. 2008; 319(5868):1352-1355.
73. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM and Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986; 57(10):2006-2021.
74. Riccardi VM and Powell PP. Neurofibrosarcoma as a complication of von Recklinghausen neurofibromatosis. Neurofibromatosis. 1989; 2(3):152-165.
75. Ferner RE and Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002; 62(5):1573-1577.
76. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE and Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999; 155(6):1879-1884.
77. Legius E, Marchuk DA, Collins FS and Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet. 1993; 3(2):122-126.
78. Glover TW, Stein CK, Legius E, Andersen LB, Brereton A and Johnson S. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer. 1991; 3(1):62-70.
79. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ and Glover TW. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 1994; 10(4):250-255.
80. Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC and Wu H. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA. 2009; 106(46):19479-19484.
81. Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH and Pappo AS. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr. 2004; 144(5):666-668.
82. Martinsson T, Sjöberg RM, Hedborg F and Kogner P. Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. Cancer Genet Cytogenet. 1997; 95(2):183-189.
83. Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B and Tonini GP. Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet A. 2003; 118A(4):309-313.
84. Stiller CA, Chessells JM and Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. British journal of cancer. 1994; 70(5):969-972.
85. Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, Schlegelberger B, Downing JR and Niemeyer CM. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene. 2007; 26(39):5816-5821.
86. Steinemann D, Arning L, Praulich I, Stuhrmann M, Hasle H, Stary J, Schlegelberger B, Niemeyer CM and Flotho C. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Haematologica. 2010; 95(2):320-323.
87. Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, De Wever I, Vermeesch JR, de Raedt T, De Paepe A, Speleman F, van Oosterom A, Messiaen L and Legius E. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet. 2006; 15(6):1015-1023.
88. Mussi C, Schildhaus H-U, Gronchi A, Wardelmann E and Hohenberger P. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res. 2008; 14(14):4550-4555.
89. Xu W, Mulligan LM, Ponder MA, Liu L, Smith BA, Mathew CG and Ponder BA. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer. 1992; 4(4):337-342.
90. Gutmann DH, Cole JL, Stone WJ, Ponder BA and Collins FS. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosomes Cancer. 1994; 10(1):55-58.
91. Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M, Cascon A, Harenberg T, Schiavi F, Pawlu C, Peczkowska M, Letizia C, Calvieri S, Arnaldi G, Klingenberg-Noftz RD, Reisch N, et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab. 2007; 92(7):2784-2792.
92. Stewart W, Traynor JP, Cooke A, Griffiths S, Onen NF, Balsitis M, Shah AA, Upadhyaya M and Tobias ES. Gastric carcinoid: germline and somatic mutation of the neurofibromatosis type 1 gene. Fam Cancer. 2007; 6(1):147-152.
93. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
94. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068.
95. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu C-J, Genovese G, Shmulevich I, Barnholtz-Sloan J, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-477.
96. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A and Parada LF. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer cell. 2005; 8(2):119-130.
97. Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M and Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene. 1999; 18(31):4450-4459.
98. Wu M, Wallace MR and Muir D. Nf1 haploinsufficiency augments angiogenesis. Oncogene. 2006; 25(16):2297-2303.
99. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell. 2010; 17(1):98-110.
100. Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, Huse J, Ladanyi M and Sander C. Integrative subtype discovery in glioblastoma using iCluster. PLoS ONE. 2012; 7(4).
101. Andersen LB, Fountain JW, Gutmann DH, Tarlé SA, Glover TW, Dracopoli NC, Housman DE and Collins FS. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet. 1993; 3(2):118-121.
102. Johnson MR, Look AT, DeClue JE, Valentine MB and Lowy DR. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci USA. 1993; 90(12):5539-5543.
103. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012; 44(9):1006-1014.
104. Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A and McArthur GA. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res. 2013; 19(17):4589-4598.
105. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-263.
106. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R and Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 2013; 3(3):338-349.
107. Whittaker SR, Theurillat J-P, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE and Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013; 3(3):350-362.
108. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216):1069-1075.
109. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, et al. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell. 2012; 150(6):1107-1120.
110. de Bruin EC, Cowell CF, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger SN, Walther Z, Wurtz A, Heynen GJ, Heideman DAM, Gomez-Roman JJ, García-Castaño A, Gong Y, Ladanyi M, Varmus H, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 2014.
111. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417):519-525.
112. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012; 44(10):1111-1116.
113. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus H-U, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012; 44(10):1104-1110.
114. Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER and Cho KR. Neurofibromin 1 (NF1) Defects Are Common in Human Ovarian Serous Carcinomas and Co-occur with TP53 Mutations. Neoplasia. 2008; 10(12):1362-1372.
115. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
116. Teschendorff AE, Journee M, Absil PA, Sepulchre R and Caldas C. Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS computational biology. 2007; 3(8):e161.
117. Ogata H, Sato H, Takatsuka J and De Luca LM. Human breast cancer MDA-MB-231 cells fail to express the neurofibromin protein, lack its type I mRNA isoform and show accumulation of P-MAPK and activated Ras. Cancer Lett. 2001; 172(2):159-164.
118. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB and Garraway LA. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2(1):82-93.
119. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-404.
120. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70.
121. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ and Ashworth A. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA. 2012; 109(8):2730-2735.
122. Wallace MD, Pfefferle AD, Shen L, McNairn AJ, Cerami EG, Fallon BL, Rinaldi VD, Southard TL, Perou CM and Schimenti JC. Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics. 2012; 192(2):385-396.
123. Lee J, Wang J, Torbenson M, Lu Y, Liu QZ and Li S. Loss of SDHB and NF1 genes in a malignant phyllodes tumor of the breast as detected by oligo-array comparative genomic hybridization. Cancer Genet Cytogenet. 2010; 196(2):179-183.
124. Ward AF, Braun BS and Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012; 120(17):3397-3406.
125. Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, Purkayastha A, Dressel A, Karp J, Bockenstedt P, Al-Zoubi A, Talpaz M, Kujawski L, Liu Y, Shedden K, Shakhan S, et al. NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res. 2010; 16(16):4135-4147.
126. Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W, Schnittger S and Haferlach T. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia. 2010; 24(5):1065-1069.
127. Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, Eclache V, Gachard N, Tigaud I, Plessis G, Cuccuini W, Geffroy S, Villenet C, Figeac M, Leprêtre F, Renneville A, et al. Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. Am J Hematol. 2013; 88(4):306-311.
128. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-2074.
129. Kolquist KA, Schultz RA, Furrow A, Brown TC, Han J-Y, Campbell LJ, Wall M, Slovak ML, Shaffer LG and Ballif BC. Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. Cancer Genet. 2011; 204(11):603-628.
130. Misawa S, Horiike S, Kaneko H and Kashima K. Genetic aberrations in the development and subsequent progression of myelodysplastic syndrome. Leukemia. 1997; 11 Suppl 3:533-535.
131. Balgobind BV, Van Vlierberghe P, van den Ouweland AMW, Beverloo HB, Terlouw-Kromosoeto JNR, van Wering ER, Reinhardt D, Horstmann M, Kaspers GJL, Pieters R, Zwaan CM, Van den Heuvel-Eibrink MM and Meijerink JPP. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008; 111(8):4322-4328.
132. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen S-C, Wei L, Collins-Underwood JR, Ma J, Roberts KG, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-163.
133. Li Y, Bollag G, Clark R, Stevens J, Conroy L, Fults D, Ward K, Friedman E, Samowitz W and Robertson M. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell. 1992; 69(2):275-281.
134. Cawkwell L, Lewis FA and Quirke P. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/ MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. British Journal of Cancer. 1994; 70(5):813-818.
135. Leggett B, Young J, Buttenshaw R, Thomas L, Young B, Chenevix-Trench G, Searle J and Ward M. Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region. British Journal of Cancer. 1995; 71(5):1070-1073.
136. Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, Dallapiccola B and Lothe RA. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia. 2008; 10(7):680-686, 682 p following 686.
137. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJP, Stinson J, Gnad F, Huntley MA, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012; 488(7413):660-664.
138. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
139. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010; 42(8):715-721.
140. Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K, Amatruda JF and Cameron S. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011; 50(6):397-408.
141. Burnichon N, Buffet A, Parfait B, Letouzé E, Laurendeau I, Loriot C, Pasmant E, Abermil N, Valeyrie-Allanore L, Bertherat J, Amar L, Vidaud D, Favier J and Gimenez-Roqueplo A-P. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet. 2012; 21(26):5397-5405.
142. Welander J, Larsson C, Bäckdahl M, Hareni N, Sivlér T, Brauckhoff M, Söderkvist P and Gimm O. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet. 2012; 21(26):5406-5416.
143. Martín Y, Dopazo A and Hernández-Chico C. Progress and challenges in developing a molecular diagnostic test for neurofibromatosis type 1. Expert Rev Mol Diagn. 2011; 11(7):671-673.
144. Ars E, Serra E, García J, Kruyer H, Gaona A, Lázaro C and Estivill X. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet. 2000; 9(2):237-247.
145. Purandare SM, Huntsman Breidenbach H, Li Y, Zhu XL, Sawada S, Neil SM, Brothman A, White R, Cawthon R and Viskochil D. Identification of neurofibromatosis 1 (NF1) homologous loci by direct sequencing, fluorescence in situ hybridization, and PCR amplification of somatic cell hybrids. Genomics. 1995; 30(3):476-485.
146. Luijten M, Wang Y, Smith BT, Westerveld A, Smink LJ, Dunham I, Roe BA and Hulsebos TJ. Mechanism of spreading of the highly related neurofibromatosis type 1 (NF1) pseudogenes on chromosomes 2, 14 and 22. European journal of human genetics: EJHG. 2000; 8(3):209-214.
147. Yu H, Zhao X, Su B, Li D, Xu Y, Luo S, Xiao C and Wang W. Expression of NF1 pseudogenes. Hum Mutat. 2005; 26(5):487-488.
148. Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F and Paepe AD. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000; 15(6):541-555.
149. Valero MC, Martín Y, Hernández-Imaz E, Marina Hernández A, Meleán G, Valero AM, Javier Rodríguezálvarez F, Tellería D and Hernández-Chico C. A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn. 2011; 13(2):113-122.
150. Sabbagh A, Pasmant E, Imbard A, Luscan A, Soares M, Blanché H, Laurendeau I, Ferkal S, Vidaud M, Pinson S, Bellanné-Chantelot C, Vidaud D, Parfait B and Wolkenstein P. NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat. 2013; 34(11):1510-1518.
151. Lenarduzzi M, Hui ABY, Alajez NM, Shi W, Williams J, Yue S, O'Sullivan B and Liu F-F. MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. PLoS ONE. 2013; 8(1).
152. Gutmann DH, McLellan MD, Hussain I, Wallis JW, Fulton LL, Fulton RS, Magrini V, Demeter R, Wylie T, Kandoth C, Leonard JR, Guha A, Miller CA, Ding L and Mardis ER. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res. 2013; 23(3):431-439.
153. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SMG, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer cell. 2009; 16(1):44-54.
154. Hollstein PE and Cichowski K. Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov. 2013; 3(8):880-893.
155. Sedani A, Cooper DN and Upadhyaya M. An emerging role for microRNAs in NF1 tumorigenesis. Hum Genomics. 2012; 6.
156. Gupta A, Cohen BH, Ruggieri P, Packer RJ and Phillips PC. Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology. 2003; 60(1):130-132.
157. Packer RJ, Gutmann DH, Rubenstein A, Viskochil D, Zimmerman RA, Vezina G, Small J and Korf B. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology. 2002; 58(10):1461-1470.
158. Babovic-Vuksanovic D, Widemann BC, Dombi E, Gillespie A, Wolters PL, Toledo-Tamula MA, O'Neill BP, Fox E, MacDonald T, Beck H and Packer RJ. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol. 2007; 36(5):293-300.
159. Babovic-Vuksanovic D, Ballman K, Michels V, McGrann P, Lindor N, King B, Camp J, Micic V, Babovic N, Carrero X, Spinner R and O'Neill B. Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology. 2006; 67(10):1860-1862.
160. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P and Balis FM. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006; 24(3):507-516.
161. Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, et al. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro-oncology. 2014; 16(5):707-718.
162. Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R and Fisher MJ. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014; 61(6):982-986.
163. Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim M-O, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013; 123(1):340-347.
164. Jakacki RI, Dombi E, Potter DM, Goldman S, Allen JC, Pollack IF and Widemann BC. Phase I trial of pegylated interferon-a-2b in young patients with plexiform neurofibromas. Neurology. 2011; 76(3):265-272.
165. Zhu Y, Ghosh P, Charnay P, Burns DK and Parada LF. Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment. Science. 2002; 296(5569):920-922.
166. Robertson KA, Nalepa G, Yang F-C, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. The Lancet Oncology. 2012; 13(12):1218-1224.
167. Yang F-C, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/--and c-kitdependent bone marrow. Cell. 2008; 135(3):437-448.
168. Lasater EA, Bessler WK, Mead LE, Horn WE, Clapp DW, Conway SJ, Ingram DA and Li F. Nf1+/-mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. Hum Mol Genet. 2008; 17(15):2336-2344.
169. Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B and Widemann BC. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer. 2013; 60(3):396-401.
170. Barkan B, Starinsky S, Friedman E, Stein R and Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res. 2006; 12(18):5533-5542.
171. Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH and Guha A. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer. 2010; 126(2):563-571.
172. Johansson G, Mahller YY, Collins MH, Kim M-O, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G and Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008; 7(5):1237-1245.
173. Zou CY, Smith KD, Zhu Q-S, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE and Lev D. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009; 8(5):1157-1168.
174. Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K-i, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y and Oda Y. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013; 19(2):450-461.
175. Li H, Velasco-Miguel S, Vass WC, Parada LF and DeClue JE. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002; 62(15):4507-4513.
176. Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR and Gutmann DH. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res. 2010; 70(4):1356-1366.
177. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong K-K, Macleod KF, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer cell. 2011; 20(3):400-413.
178. Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ and Ratner N. Ras-driven transcriptome analysis identifies aurora kinase a as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res. 2012; 18(18):5020-5030.
179. Hirokawa Y, Nheu T, Grimm K, Mautner V, Maeda S, Yoshida M, Komiyama K and Maruta H. Sichuan pepper extracts block the PAK1/cyclin D1 pathway and the growth of NF1-deficient cancer xenograft in mice. Cancer Biol Ther. 2006; 5(3):305-309.
180. Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H and Maruta H. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyrkinase inhibitors). Cancer Lett. 2007; 245(1-2):242-251.
181. See WL, Tan IL, Mukherjee J, Nicolaides T and Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res. 2012; 72(13):3350-3359.
182. Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature. 2009; 461(7262):411-414.
183. Dodd RD, Mito JK, Eward WC, Chitalia R, Sachdeva M, Ma Y, Barretina J, Dodd L and Kirsch DG. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther. 2013; 12(9):1906-1917.
184. Petrilli A, Bott M and Fernandez-Valle C. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis. Oncotarget. 2013; 4(12):2354-2365.
185. Mashiach-Farkash E, Rak R, Elad-Sfadia G, Haklai R, Carmeli S, Kloog Y and Wolfson HJ. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget. 2012; 3(6):629-639.
186. Rak R and Kloog Y. Targeting LIM kinase in cancer and neurofibromatosis. Cell cycle (Georgetown, Tex). 2014; 13(9):1360-1361.